SEARCH

SEARCH BY CITATION

References

  • ABADJI, V., LIN, S., TAHA, G., GRIFFIN, G., STEVENSON, L.A., PERTWEE, R.G. & MAKRIYANNIS, A. (1994). (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem., 37, 18891893.
  • BAYEWITCH, M., AVIDOR-REISS, T., LEVY, R., BARG, J., MECHOULAM, R. & VOGEL, Z. (1995). The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett., 375, 143147.
  • BEGG, M., DALE, N., LLAUDET, E., MOLLEMAN, A. & PARSONS, M.E. (2002). Modulation of the release of endogenous adenosine by cannabinoids in the myenteric plexus-longitudinal muscle preparation of the guinea-pig ileum. Br. J. Pharmacol., 137, 12981304.
  • BROWN, A.J. & WISE, A. (2001). Identification of modulators of GPR55 activity. Patent number, WO0186305.
  • BROWN, A.J., UENO, S., SUEN, K., DOWELL, S.J. & WISE, A. (2005). Molecular identification of GPR55 as a third G protein-coupled receptor responsive to cannabinoid ligands. ICRS Symposium on the cannabinoids, http://www.cannabinoidsociety.org.
  • DEL CARMEN GARCÍA, M., ADLER-GRASCHINSKY, E. & CELUCH, S.M. (2003). Hypotensive effect of anandamide through the activation of CB1 and VR1 spinal receptors in urethane-anesthetized rats. Naunyn Schmiedebergs Arch. Pharmacol., 368, 270276.
  • DRMOTA, T., GREASLEY, P. & GROBLEWSKI, T. (2004). Screening assays for cannabinoid-ligand type modulators of GPR55. Patent number, WO2004074844.
  • ELLIS, E.F., MOORE, S.F. & WILLOUGHBY, K.A. (1995). Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin. Am. J. Physiol., 269, H1859H1864.
  • FACCI, L., DAL TOSO, R., ROMANELLO, S., BURIANI, A., SKAPER, S.D. & LEON, A. (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. U.S.A., 92, 33763380.
  • FORD, W.R., CLANACHAN, A.S., HILEY, C.R. & JUGDUTT, B.I. (2001). Angiotensin II reduces infarct size and has no effect on post-ischaemic contractile dysfunction in isolated rat hearts. Br. J. Pharmacol., 134, 3845.
  • FORD, W.R., HONAN, S.A., WHITE, R. & HILEY, C.R. (2002). Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br. J. Pharmacol., 135, 11911198.
  • FRIDE, E., FOOX, A., ROSENBERG, E., FAIGENBOIM, M., COHEN, V., BARDA, L., BLAU, H. & MECHOULAM, R. (2003). Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a ‘CB3’ receptor. Eu. J. Pharmacol., 461, 2734.
  • GLASS, M. & NORTHUP, J.K. (1999). Agonist selective regulation of G proteins by cannabinoid CB1 and CB2 receptors. Mol. Pharmacol., 56, 13621369.
  • GOPARAJU, S.K., UEDA, N., YAMAGUCHI, H. & YAMAMOTO, S. (1998). Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett., 422, 6973.
  • HILLARD, C.J., MANNA, S., GREENBERG, M.J., DICAMELLI, R., ROSS, R.A., STEVENSON, L.A., MURPHY, V., PERTWEE, R.G. & CAMPBELL, W.B. (1999). Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. Pharmacol. Exp. Ther., 289, 14271433.
  • HUFFMAN, J.W., LIDDLE, J., YU, S., AUNG, M.M., ABOOD, M.E., WILEY, J.L. & MARTIN, B.R. (1999). 3-(1′,1′-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg. Med. Chem., 7, 29052914.
  • JÁRAI, Z., WAGNER, J.A., VARGA, K., LAKE, K.D., COMPTON, D.R., MARTIN, B.R., ZIMMER, A.M., BONNER, T.I., BUCKLEY, N.E., MEZEY, E., RAZDAN, R.K., ZIMMER, A. & KUNOS, G. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U.S.A., 96, 1413614141.
  • JOYEUX, M., ARNAUD, C., GODIN-RIBUOT, D., DEMENGE, P., LAMONTAGNE, D. & RIBUOT, C. (2002). Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc. Res., 55, 619625.
  • KOZAK, K.R., CREWS, B.C., MORROW, J.D., WANG, L.H., MA, Y.H., WEINANDER, R., JAKOBSSON, P.J. & MARNETT, L.J. (2002). Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J. Biol. Chem., 277, 4487744885.
  • KWOLEK, G., ZAKRZESKA, A., SCHLICKER, E., GOTHERT, M., GODLEWSKI, G. & MALINOWSKA, B. (2005). Central and peripheral components of the pressor effect of anandamide in urethane-anaesthetized rats. Br. J. Pharmacol., 145, 567575.
  • LAGNEUX, C. & LAMONTAGNE, D. (2001). Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br. J. Pharmacol., 132, 793796.
  • LAINE, K., JARVINEN, K., MECHOULAM, R., BREUER, A. & JARVINEN, T. (2002). Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest. Ophthalmol. Vis. Sci., 43, 32163222.
  • LAMBERT, D.M., DIPAOLO, F.G., SONVEAUX, P., KANYONYO, M., GOVAERTS, S.J., HERMANS, E., BUEB, J., DELZENNE, N.M. & TSCHIRHART, E.J. (1999). Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB2 cannabinoid, as potential ligands for the cannabinoid receptors. Biochim. Biophys. Acta, 1440, 266274.
  • LÉPICIER, P., BOUCHARD, J.F., LAGNEUX, C. & LAMONTAGNE, D. (2003). Endocannabinoids protect the rat isolated heart against ischaemia. Br. J. Pharmacol., 139, 805815.
  • LÓPEZ-MIRANDA, V., HERRADON, E., DANNERT, M.T., ALSASUA, A. & MARTÍN, M.I. (2004). Anandamide vehicles: a comparative study. Eur. J. Pharmacol., 505, 151161.
  • MALINOWSKA, B., KWOLEK, G. & GOTHERT, M. (2001). Anandamide and methanandamide induce both vanilloid VR1- and cannabinoid CB1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats. Naunyn Schmiedebergs Arch. Pharmacol., 364, 562569.
  • MATSUDA, L.A., LOLAIT, S.J., BROWNSTEIN, M.J., YOUNG, A.C. & BONNER, T.I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561564.
  • MECHOULAM, R., FRIDE, E. & DI MARZO, V. (1998). Endocannabinoids. Eur. J. Pharmacol., 359, 118.
  • MO, F.M., OFFERTÁLER, L. & KUNOS, G. (2004). Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. Eur. J. Pharmacol., 489, 2127.
  • MUNRO, S., THOMAS, K.L. & ABU-SHAAR, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 6165.
  • PERTWEE, R.G. (1999). Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem., 6, 635664.
  • SMART, D., GUNTHORPE, M.J., JERMAN, J.C., NASIR, S., GRAY, J., MUIR, A.I., CHAMBERS, J.K., RANDALL, A.D. & DAVIS, J.B. (2000). The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol., 129, 227230.
  • STEFFENS, M., ZENTNER, J., HONEGGER, J. & FEUERSTEIN, T.J. (2005). Binding affinity and agonist activity of putative endogenous cannabinoids at the human neocortical CB1 receptor. Biochem. Pharmacol., 69, 169178.
  • SUGIURA, T., KONDO, S., KISHIMOTO, S., MIYASHITA, T., NAKANE, S., KODAKA, T., SUHARA, Y., TAKAYAMA, H. & WAKU, K. (2000). Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem., 275, 605612.
  • UNDERDOWN, N.J. & FORD, W.R. (2004). Anandamide reduces infarct size in rat isolated hearts by a mechanism independent of CB1 or CB2 receptor activation. Proc. Br. Pharmacol. Soc., at http://www.pa2online.org/Vol2Issue2abst091P.html.
  • VOGEL, Z., BARG, J., LEVY, R., SAYA, D., HELDMAN, E. & MECHOULAM, R. (1993). Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J. Neurochem., 61, 352355.
  • ZORATTI, C., KIPMEN-KORGUN, D., OSIBOW, K., MALLI, R. & GRAIER, W.F. (2003). Anandamide initiates Ca2+ signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells. Br. J. Pharmacol., 140, 13511362.